for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-GSK, Vir To Test Giving Sotrovimab Intramuscularly For Mild-To-Moderate COVID-19

June 21 (Reuters) - GlaxoSmithKline Plc:

* GSK AND VIR BIOTECHNOLOGY ANNOUNCE CONTINUING PROGRESS OF THE COMET CLINICAL DEVELOPMENT PROGRAMME FOR SOTROVIMAB

* ANALYSIS CONFIRMS SOTROVIMAB REDUCES HOSPITALISATION, RISK OF DEATH IN ADULTS WITH MILD-TO-MODERATE COVID-19 AT HIGH RISK OF PROGRESSION TO SEVERE DISEASE

* FURTHER RESEARCH INITIATED TO EVALUATE INTRAMUSCULAR ADMINISTRATION OF SOTROVIMAB FOR EARLY TREATMENT OF MILD-TO-MODERATE COVID-19 Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up